Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

I am Tran Tin Hien, I am a physician working with OUCRU in Ho Chi Minh City Vietnam. The first unit was established in Ho Chi Minh City in 1990, and ten years later we had a sub-unit in Hanoi.

Most diseases in the tropics are infectious diseases: malaria, dengue haemorrhagic fevers, encephalitis, even flu; Ebola in other countries but not in Vietnam. In Vietnam, 20 years ago malaria was at the top with more than 1 million cases in the whole country, but now the incidence has decreased. But the incidence of dengue haemorrhagic fever is still high, with more than 100,000 cases in the whole country. I think to reduce the burden of disease in Vietnam we have to strengthen the health care network because if we have a good start with skills, physicians, nurses, and technicians with the right equipment we can make an early diagnosis and treatment, and in infectious diseases, early diagnosis and treatment help reduce the mortality and the morbidity.

With infectious diseases I think blood culture is crucial practice in laboratory to confirm diagnosis, but now we have all the molecular tools, like for example PCR, and all the machines to make automatic blood culture, so we can improve the quality of diagnosis.

Over the last 10 years, we have conducted the most important study in monitoring the resistance of the Plasmodium falciparum malaria parasite to the most powerful anti-malaria drug: artemisinin and artemisinin combination therapy. Now, in South East Asia the treatment failure to that drug artemisinin is high, yesterday I think it was 50%. That means that in two patients with malaria, in Vietnam, that you treat with artemisinin, one fails; you cannot cure the patient, you have to find another combination or a new drug to treat the patient.

Vietnam is a low and middle income country. Even in health care, despite lots of investment from the government we are still lacking money, that means lacking staff, lacking equipment, so the investment has to improve the health through clinical research. Because the burden of infectious diseases in Vietnam is still high with dengue haemorrhagic fever, with malaria, with hand-foot-mouth disease and all the viral infections, we have to invest money to improve good diagnosis and management.

From the beginning we have conducted studies to test what we knew in the laboratory, to apply in clinical trials and then apply to the community. That means three steps of translational medicine: bench side, bedside and then community, and all three steps fit into the translational medicine policy of the department.

Tran Hien

OUCRU Vietnam

Professor Hien’s research focuses on infectious diseases of public health importance in Vietnam, a collaboration between OUCRU and the Hospital for Tropical Diseases in Ho Chi Minh City. Research projects aims to quantify the burden of infectious diseases and design clinical trials to improve diagnosis and treatment.

More podcasts related to Global Health

Mike English: Health services that deliver for newborns

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Juan Carrique-Mas: Antimicrobial resistance in poultry production

Many households in Vietnam raise animals for food production, particularly chickens, using large amounts of antimicrobials with no veterinary support, and those antimicrobials find their way into the food chain. The ViParc project conducts intervention trials similar to human clinical trials, to help farmers reduce the level of antimicrobials used when raising chickens.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.